Standout Papers

Sunitinib Malate for the Treatment of Pancreatic Neuroendoc... 2002 2026 2010 2018 1.8k
  1. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors (2011)
    Éric Raymond, Laëtitia Dahan et al. New England Journal of Medicine
  2. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer (2005)
    Sandrine Faivre, Catherine Delbaldo et al. Journal of Clinical Oncology
  3. Current development of mTOR inhibitors as anticancer agents (2006)
    Sandrine Faivre, Guido Kroemer et al. Nature Reviews Drug Discovery
  4. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types (2002)
    José Baselga, Danny Rischin et al. Journal of Clinical Oncology
  5. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial (2013)
    Ann‐Lii Cheng, Yoon‐Koo Kang et al. Journal of Clinical Oncology
  6. Molecular basis for sunitinib efficacy and future clinical development (2007)
    Sandrine Faivre, George D. Demetri et al. Nature Reviews Drug Discovery
  7. Oxaliplatin: A review of preclinical and clinical studies (1998)
    Éric Raymond, Stephen G. Chaney et al. Annals of Oncology
  8. mTOR-targeted therapy of cancer with rapamycin derivatives (2005)
    Stéphane Vignot, Sandrine Faivre et al. Annals of Oncology
  9. Targeting the TGFβ pathway for cancer therapy (2014)
    Cindy Neuzillet, Annemilaï Tijeras‐Raballand et al. Pharmacology & Therapeutics
  10. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas (2016)
    Rocio García‐Carbonero, Halfdan Sørbye et al. Neuroendocrinology

Immediate Impact

2 by Nobel laureates 5 from Science/Nature 102 standout
Sub-graph 1 of 14

Citing Papers

Small molecules, big impact: 20 years of targeted therapy in oncology
2020 Standout
Hepatocellular Carcinoma
2019 Standout
41 intermediate papers

Works of Éric Raymond being referenced

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013 Standout
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
2008
and 11 more

Author Peers

Author Last Decade Papers Cites
Éric Raymond 10556 8626 4391 364 20.8k
Emilio Bajetta 10203 3860 5759 323 16.3k
Peter J. O’Dwyer 12800 9732 5123 394 23.0k
Asif Rashid 9534 4767 4212 301 19.8k
Jordan Berlin 15107 6464 6177 351 22.4k
Sandrine Faivre 6717 6568 3320 284 14.6k
Patrick Schöffski 9407 4736 9276 500 18.9k
Filippo de Braud 17473 5605 8522 749 26.0k
Takuji Okusaka 10422 3277 4582 527 18.9k
Alan P. Venook 9629 3043 3744 361 17.1k
David S. Hong 10195 9319 6145 810 22.5k

All Works

Loading papers...

Rankless by CCL
2026